Maraviroc

Maraviroc

Maraviroc

InformationMaraviroc (UK-427857) Maraviroc (UK-427857) is a CCR5 antagonist for MIP-1α , MIP-1β and RANTES with IC50 of 3.3 nM, 7.2 nM and 5.2 nM in cell-free assays, respectively. Maraviroc is used in the treatment of HIV

An antagonist of the CCR5 receptor, inhibiting binding of the ligand RANTES with an IC₅₀ value of 1.4 nM inhibits HIV-1 replication in CCR5-expressing cells (IC₅₀ = 2.8 nM).

An antagonist of the CCR5 receptor, inhibiting binding of the ligand RANTES with an IC₅₀ value of 1.4 nM inhibits HIV-1 replication in CCR5-expressing cells (IC₅₀ = 2.8 nM).

An antagonist of the CCR5 receptor, inhibiting binding of the ligand RANTES with an IC₅₀ value of 1.4 nM inhibits HIV-1 replication in CCR5-expressing cells (IC₅₀ = 2.8 nM).

An antagonist of the CCR5 receptor, inhibiting binding of the ligand RANTES with an IC₅₀ value of 1.4 nM inhibits HIV-1 replication in CCR5-expressing cells (IC₅₀ = 2.8 nM).

Vicriviroc Malate is a potent CKR-5 (CCR5) antagonist with IC|50|of 0.91 nM. Vicriviroc has a higher binding affinity to CCR5 as opposed to SCH-C in competition binding assays. Vicriviroc is close to 6-fold less active than SCH-C in attenuating

Vicriviroc Malate is a potent CKR-5 (CCR5) antagonist with IC|50|of 0.91 nM. Vicriviroc has a higher binding affinity to CCR5 as opposed to SCH-C in competition binding assays. Vicriviroc is close to 6-fold less active than SCH-C in attenuating

Biochem/physiol Actions Vicriviroc is an orally available, potent and selective allosteric antagonist of C-C chemokine CCR5 receptors. Vicriviroc inhibits the interaction of HIV-1 with CCR5 receptor thereby preventing HIV-1 virus entry into cells.

Biochem/physiol Actions Vicriviroc is an orally available, potent and selective allosteric antagonist of C-C chemokine CCR5 receptors. Vicriviroc inhibits the interaction of HIV-1 with CCR5 receptor thereby preventing HIV-1 virus entry into cells.